Beyond the Eyes: Is Teprotumumab Effective for Thyroid Dermopathy?
Thyroid® · 01.02.2026 · 36 (2) · 213-218
DOI: 10.1177/10507256251414948 ↗Kurz gefasst
Fallbericht in der Zeitschrift Thyroid®, online erschienen am 13.01.2026. Verfasst von Dana Hamadi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hennepin Healthcare, Minneapolis, MN, USA. Hauptthemen laut MEDLINE: Graves Ophthalmopathy, Graves Disease, Antibodies, Monoclonal, Humanized, Skin Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Background
Pretibial dermopathy (PTD) is a rare, disfiguring manifestation of Graves’ disease. The shared pathophysiology with thyroid eye disease (TED), centered on fibroblast activation via a thyroid-stimulating hormone receptor and insulin-like growth factor-1 receptor (IGF-1R) complex, provides a strong rationale for using the IGF-1R inhibitor, teprotumumab.
Methods
We present a case series of five patients with severe PTD and concomitant TED who were treated with teprotumumab. A review of reported cases in the literature was also conducted.
Results
All patients experienced significant clinical improvement, including regression of skin thickening as well as enhanced functional capacity. Side effects included mild hearing loss, muscle cramps, and fatigue. One patient experienced a severe gastrointestinal event requiring treatment discontinuation, while those experiencing a recurrence of PTD, responded to a second course of therapy.
Conclusions
Teprotumumab showed promising efficacy in the treatment of PTD. Further studies are needed to confirm its durability and safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Hennepin Healthcare, Minneapolis, MN, USA.
- Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN, USA.
ORCID-Profile: Dana Hamadi
Zitieren
APA
Hamadi, D., Saad-Omer, S., Toro-Tobon, D., & Stan, M. N. (2026). Beyond the Eyes: Is Teprotumumab Effective for Thyroid Dermopathy?. Thyroid®, 36(2), 213-218. https://doi.org/10.1177/10507256251414948
Vancouver
Hamadi D, Saad-Omer S, Toro-Tobon D, Stan MN. Beyond the Eyes: Is Teprotumumab Effective for Thyroid Dermopathy?. Thyroid®. 2026;36(2):213-218. doi:10.1177/10507256251414948
BibTeX
@article{Hamadi2026,
author = {Hamadi, Dana and Saad-Omer, Suhail and Toro-Tobon, David and Stan, Marius N},
title = {Beyond the Eyes: Is Teprotumumab Effective for Thyroid Dermopathy?},
journal = {Thyroid®},
year = {2026},
volume = {36},
number = {2},
pages = {213--218},
doi = {10.1177/10507256251414948}
}
EUVIMED